Axsome Therapeutics (AXSM) Stock Price, News & Analysis

Company Overview

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. The company uses differentiated product candidates and targeted mechanisms to address conditions with significant unmet medical needs, including depression, sleep disorders, migraine, and other neurological or psychiatric diseases.

Axsome’s lead commercial product is Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride), an oral medicine approved in the United States for the treatment of major depressive disorder in adults. The company also commercializes Sunosi (solriamfetol), which is approved to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Axsome acquired the U.S. rights to Sunosi from Jazz Pharmaceuticals in 2022.

The company maintains a pipeline of investigational CNS therapies, including candidates being evaluated for disorders such as Alzheimer’s disease agitation, migraine, narcolepsy-related cataplexy, and fibromyalgia. Axsome was founded in 2012 and is headquartered in New York. Its operations and commercial activities are primarily focused on the United States. The company is led by founder and Chief Executive Officer Herriot Tabuteau, M.D.

Key Stats

• Today's Range: $156.09 to $160.43
• 50-Day Range: $156.32 to $220.89
• 52-Week Range: $123.50 to $260.19
• Volume: 873,075 shs
• Average Volume: 760,885 shs
• Market Capitalization: $8.23 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $275.74
• Consensus Rating: Moderate Buy

Axsome Therapeutics Stock Analysis - MarketRank™

Axsome Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 335th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Axsome Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 17 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Axsome Therapeutics has a consensus price target of $275.74, representing about 75.5% upside from its current price of $157.14.

Amount of Analyst Coverage

Axsome Therapeutics has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Axsome Therapeutics are expected to grow in the coming year, from ($2.92) to $3.78 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Axsome Therapeutics is -41.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Axsome Therapeutics is -41.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Axsome Therapeutics has a P/B Ratio of 89.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.95% of the float of Axsome Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Axsome Therapeutics has a short interest ratio ("days to cover") of 4.36.

Change versus previous month

Short interest in Axsome Therapeutics has recently increased by 5.31%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Axsome Therapeutics does not currently pay a dividend.

Dividend Growth

Axsome Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.31

News Sentiment

Axsome Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Axsome Therapeutics this week, compared to 8 articles on an average week.

Search Interest

34 people have searched for AXSM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

10 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,624,805.00 in company stock.

Percentage Held by Insiders

20.60% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

81.49% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:AXSM
• CIK: 1579428
• Web: axsome.com
• Phone: (212) 332-3241
• Fax: 212-320-0245
• Employees: 925
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Axsome Therapeutics: $275.74
• High Price Target: $380.00
• Low Price Target: $205.00
• Potential Upside/Downside: +75.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$183.17 million
• Net Margins: -24.68%
• Pretax Margin: -24.61%
• Return on Equity: -265.55%
• Return on Assets: -28.10%

Debt

• Debt-to-Equity Ratio: 1.52
• Current Ratio: 1.43
• Quick Ratio: 1.34

Sales & Book Value

• Annual Sales: $638.50 million
• Price / Sales: 12.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.75 per share
• Price / Book: 89.79

Miscellaneous

• Outstanding Shares: 52,380,000
• Free Float: 41,591,000
• Market Cap: $8.23 billion
• Optionable: Optionable
• Beta: 0.86